Skip to content
Study details
Enrolling now

Testing Shorter Radiation Therapy for High-Risk Prostate Cancer

NRG Oncology
NCT IDNCT05946213ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

1,209

Study length

about 12 years

Ages

18+

Sex

Male only

Locations

388 sites in AL, AR, CA +39

What this study is about

This trial is testing whether shorter duration radiation therapy, using a higher dose per treatment over two weeks, can prevent prostate cancer from returning as well as the usual longer duration radiation therapy (20 to 45 treatments over 4 to 9 weeks). It involves collecting biospecimens and imaging scans to assess the effectiveness of this new approach.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Quality-of-Life Assessment
  • 2.Questionnaire Administration
  • 3.Receive External Beam Radiation Therapy
  • +3 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Secondary: Fatigue, Incidence of adverse events (AEs), Overall survival

Procedures

diagnostic, imaging, radiation

Body systems

Oncology